Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
4.240
+0.180 (4.43%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Kezar Life Sciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Net Income
-83.74-101.87-68.24-54.63-41.74
Upgrade
Depreciation & Amortization
1.041.071.021.511.54
Upgrade
Other Amortization
0.260.240.210.09-
Upgrade
Asset Writedown & Restructuring Costs
1.552.91---
Upgrade
Loss (Gain) From Sale of Investments
-5.04-6.83-1.41.770.32
Upgrade
Stock-Based Compensation
13.0118.1414.017.64.94
Upgrade
Other Operating Activities
0.0100.01--
Upgrade
Change in Accounts Payable
-3.156.351.811.220.31
Upgrade
Change in Other Net Operating Assets
1.85-1.64-6.270.01-2.32
Upgrade
Operating Cash Flow
-74.21-81.65-58.85-42.44-36.95
Upgrade
Capital Expenditures
-0.03-1.81-1.58-0.32-0.19
Upgrade
Sale of Property, Plant & Equipment
-0.01---
Upgrade
Investment in Securities
80.4677.85-89.81-28.13-56.3
Upgrade
Investing Cash Flow
80.4376.05-91.39-28.44-56.5
Upgrade
Long-Term Debt Issued
---9.53-
Upgrade
Net Debt Issued (Repaid)
---9.53-
Upgrade
Issuance of Common Stock
0.10.64127.86103.0599.64
Upgrade
Financing Cash Flow
0.10.64127.86112.5999.64
Upgrade
Foreign Exchange Rate Adjustments
-0.06-0-0.05-0.050.08
Upgrade
Net Cash Flow
6.26-4.96-22.4341.656.28
Upgrade
Free Cash Flow
-74.24-83.46-60.42-42.75-37.14
Upgrade
Free Cash Flow Margin
--1192.21%---
Upgrade
Free Cash Flow Per Share
-10.18-11.50-8.97-8.10-8.44
Upgrade
Cash Interest Paid
1.341.320.970.07-
Upgrade
Levered Free Cash Flow
-45.24-39.23-36-22.7-21.69
Upgrade
Unlevered Free Cash Flow
-44.5-38.5-35.47-22.69-21.69
Upgrade
Change in Net Working Capital
2.81-9.884.44-2.681.14
Upgrade
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q